A 1 -A 2 9 8 Aspergillus, Candida and Cryptococcus spp. infections who are refractory to or intolerant of conventional amphotericin B. The model was built from a hospital perspective, and included drug acquisition costs and costs for treating drugrelated adverse events (AEs) within a hospital stay. The treatment duration of L-AmB and ABLC and rates of AEs for these two treatments were mainly obtained from a retrospective study of these two drugs in the target population using Cerner's Health Facts data. Treatment costs of AEs were obtained from publicly available sources. The budget impact (2011USD) was evaluated by changing the market share of L-AmB and ABLC from 50/50% to 80/20%. One-way sensitivity analyses were conducted by varying drug cost, treatment duration, and rates and costs of AEs. RESULTS: The per-patient costs associated with L-AmB and ABLC during one hospital stay were $14,563 and $16,748, respectively. Cost of AEs attributed to 68.7% of the costs for L-AmB and 85.4% for ABLC. In a hypothetical hospital with 100 annual admissions of patients using one of these two drugs for fungal infections, changing the market shares from 50/50% for L-AmB and ABLC, respectively, to 80/20% yielded a cost saving of $65,561. Sensitivity analyses indicated that the results were robust to changes in input parameter values. CONCLUSIONS: This study suggests that hospitals can realize cost savings by substituting ABLC with L-AmB in the treatment of invasive fungal infections. The cost savings are driven by the lower rates of AEs associated with L-AmB compared to ABLC.
OBJECTIVES: Skin and soft tissue infections (SSTI) are common and complicated SSTIs (cSSTI) is the more extreme end of this clinical spectrum. The aim of this analysis is to estimate the budget impact of Linezolid in the treatment of cSSTI in Colombia. METHODS: A model was built with a horizon of three years. The comparators were: Linezolid (600mg IV/twice day) switch (600 orally/twice day) compared with Vancomycin (1 g IV/twice day), Daptomycin (4 mg IV/kg/day) and Tigecycline (100 mg IV followed by 50 mg twice day). The analysis used the third payer perspective including only direct medical costs. Costs were taken from health care institutions. Resource use and costs (drug acquisition, inpatient stay, health care professional visits, and lab tests). Costs were expressed in 2012 $ US. The calculation of patients likely to be treatment was estimate using data published in the literature on the incidence of patients hospitalized for SSTI and the percentage of methicillin-resistant Staphylococcus aureus (MRSA) in cSSTI, this data were applied the Colombian population projected by the national administrative department of statistics for 2012. Univariate sensitivity analyses were performed. RESULTS: With an incidence of 0.16 hospitalizations for SSTI per 10,000 hospital visits per year, and considering the market share growth of Linezolid from 15% to 35% over 3 years, the model showed a reduction of approximately $ US 15,609,105.97 in total costs for disease treatment . If the market share of Linezolid would be increased 1% there could be savings for $ US 460,428.26 (first year). CONCLUSIONS: Linezolid is a favorable alternative for the treatment of cSSTI, considering the lower cost of treatment per patient ($ US 8, 226.25 ) per year compared with other available antimicrobial therapies, which would mean relevant savings in the context of health system in this country.
PIN29 THE ECONOMIC IMPACT OF LINEZOLID FOR THE MANAGEMENT OF COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI) IN THE CHILEAN PREVISIONAL HEALTH INSTITUTIONS (ISAPRE)
Mould-Quevedo JF 1 , Vargas Zea N 2 , Diaz-Sotelo OD 3 , Villamil Munevar V 4 , Vecino Ortiz A 5 1 Pfizer, Inc., New York, NY, USA, 2 Pfizer S. A.S., Bogota, Colombia, 3 RANDOM Foundation, Bogota, DC, Colombia, 4 RANDOM Foundation, Bogota, Colombia, 5 Johns Hopkins University, Baltimore, MD, MD, USA OBJECTIVES: Complicated skin and soft tissue infections (cSSTIs) are ones of the largest reasons for increased hospitalization; these are often attributed to Staphylococcus aureus and Streptococcus pyogenes which represent a major health burden that soar health care costs. The aim of this analysis is to estimate the impact on the budget of linezolid in the treatment of cSSTI in the Chilean private scenario. METHODS: A budgetary model was built within a time horizon of three years. Antimicrobial therapies used were: linezolid (1200 mg/day), vancomycin (2 mg/day), daptomycin (350 mg/day) and tigecycline (100 mg/day). The private payer's perspective was used considering direct medical costs only. Resource use and costs of acquisition drug, inpatient stay, health care professional visits, and lab test, were collected from health care institutions from the private sector (Previsional Health Institutions -ISAPRE). Incidence of hospitalization due to cSSTI and percentage of methicillin-resistant Staphylococcus aureus (MRSA) in cSSTI were taken from literature and applied to the Chilean estimated population. Costs are in 2012 USD. RESULTS: Assuming a market share growth from 15% to 35% over three years with Linezolid, and taking into account 0.164% incidence of hospitalized skin and skin structure infections and a percentage of MRSA in cSSTI of 58%. The model showed a reduction of approximately US$343.18 per patient in total costs for disease treatment (US$101,834,379.86 for all included population [n=296,735]) due to lower time in UCI and lower costs for outpatient treatment. CONCLUSIONS: Considering the savings generated in the total treatment (drugs and medical costs for inpatient and outpatient treatment) of cSSTI with linezolid compared with other available antimicrobial therapies, Linezolid is the treatment of choice by meaning savings in the context of Previsional Health Institutions (ISAPRE) in Chile.
PIN30 BUDGET IMPACT ANALYSIS OF LINEZOLID IN THE TREATMENT OF COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI) IN CHILE -PUBLIC SCENARIO
Mould-Quevedo JF 1 , Vargas Zea N 2 , Diaz-Sotelo OD 3 , Villamil Munevar V 4 , Vecino Ortiz A 5 1 Pfizer, Inc., New York, NY, USA, 2 Pfizer S.A.S., Bogota, Colombia, 3 RANDOM Foundation, Bogota, DC, Colombia, 4 RANDOM Foundation, Bogota, Colombia, 5 Johns Hopkins University, Baltimore, MD, MD, USA OBJECTIVES: Skin and soft tissue infections (SSTI) is a common cause of morbidity, both in the community and within hospitals. Its treatment is limited to the increased likelihood of methicillin-resistant Staphylococcus Aureus (MRSA) which has been identified as the predominant cause of SSTI. In case of complicated SSTI (cSSTI) the probability of hospitalization raises generating higher health care costs. Therefore, the aim of this analysis was to estimate the budgetary impact of linezolid in the treatment of cSSTI from the Chilean public payer's perspective. METHODS: A model was built within a three years timeframe to estimate the financial impact of different authorized therapies for cSSTI. Comparators were: linezolid (1200 mg/day), vancomycin (2 mg/day), daptomycin (350 mg/day) and tigecycline (100 mg/day). Only direct medical costs were considered. Resource use and costs (acquisition drug, inpatient stay, health care professional visits, and lab tests) were retrieved from Chilean health care institution databases (National Fund of Health -FONASA). Calculation of patients likely to be treatment was estimate using data published in the literature about the incidence of patients hospitalized SSTI and percentage of MRSA in cSSTI. Costs were expressed in 2012 US$ and univariate sensitivity analyses were performed. RESULTS: With an incidence of 0.164 hospitalizations for SSTI in the public sector per 10,000 hospital visits per year, and considering a market share growth of linezolid from 15% to 35% over three years, the model showed a reduction of approximately US$65,577.05 in overall costs for disease treatment (US$4 per patient); if the market share of linezolid would be increased 1% there could be savings for US$608,207.8 (first year). CONCLUSIONS: Linezolid is a favorable therapy for the treatment of cSSTI, considering the lower cost of treatment per patient (US$3489) compared with other available antimicrobial therapies, which would mean relevant savings to the National Fund of Health (FONASA) in Chile.
PIN31 BUDGET IMPACT EVALUATION OF A PNEUMOCOCCAL CONJUGATED VACCINE (PCV) 13 VALENT VACCINATION WITH FREE CAMPAIGN PROGRAM FOR CORPORATIONS VESUS NO VACCINATION FOR OLDER ADULTS
Fujii RK 1 , Presa J 1 , Roberts CS 2 , Gea Y 1 , Manfrin DF 1 , Mould J 2 1 Pfizer, Inc., São Paulo, Brazil, 2 Pfizer, New York, NY, USA OBJECTIVES: Pneumococcal disease is a public health concern worldwide. This study evaluates the budget impact of PCV 13 vaccination with free campaign for corporations, versus no vaccination for individuals with 60+ years of age. METHODS: A budget impact analysis was developed considering vaccination costs, wage and productivity loss from employee absence due to sickness or death. Clinical events were calculated using a Markov model with individuallevel simulation considering a cohort of 1.000.000 individuals of 60 years of age in a time horizon of 5 years, assuming a retirement age of 65. Vaccines effectiveness' were extrapolated from infant results. Absence days due to health events were retrieved from national labor legislations. Average wage was retrieved from the Brazilian Institute for Geography and Statistics (IBGE) 2012 data and productivity was estimated from the indicator 'revenue generated by the employee', from a market research developed by Exame magazine in 2012 using IBGE and the Brazilian Central Bank data. The base case considered a large corporation in Brazil with approximately 4.000 eligible individuals. Values were expressed in 2012 US$. RESULTS: PCV13 with free campaign totaled US$61,40 per employee. Productivity loss due to sick leave and death per employee was respectively US$641,97 and US$712,61 for PCV13 and no vaccination. Considering all evaluated costs per employee and the number of eligible individuals, PCV13 and no vaccination totaled US$2.813.483,66 and US$2.850.451,98 respectively, representing US$36.968,32 of total savings for PCV13 vaccination when compared to no vaccination. CONCLUSIONS: The PCV13 vaccination plus a free campaign initiative is estimated to save costs to the employee, when compared to no vaccination, mainly driven by productivity loss due to sick leave and death, which represented 115,52% of the total investment in a time horizon of 5 years for individuals of 60+ years of age.
PIN32 BUDGET IMPACT EVALUATION OF A VACCINATION WITH CAMPAIGN PROGRAM FOR CORPORATIONS USING PNEUMOCOCCAL CONJUGATED VACCINE (PCV) 13 VALENT VERSUS PNEUMOCOCCAL POLISACCHARIDE VACCINE (PPV) 23 WITH PAID CAMPAIGN FOR OLDER ADULTS

